Molecular Basis for the Lack of HERG K+ Channel Block-Related Cardiotoxicity by the H1 Receptor Blocker Cetirizine Compared with Other Second-Generation Antihistamines

Abstract

In the current study, the potential blocking ability of K+channels encoded by the human ether-a-go-go related gene (HERG) by the piperazine H1 receptor antagonist cetirizine has been examined and compared with that of other second-generation antihistamines (astemizole, terfenadine, and loratadine). Cetirizine was completely devoid of any inhibitory action on HERG K+ channels heterologously expressed inXenopus laevis oocytes in concentrations up to 30 μm. On the other hand, terfenadine and astemizole effectively blocked HERG K+ channels with nanomolar affinities (the estimated IC50 values were 330 and 480 nm, respectively), whereas loratadine was ∼300-fold less potent (IC50 ≈ 100 μm). In addition, in contrast to terfenadine, cetirizine did not show use-dependent blockade. In SH-SY5Y cells, a human neuroblastoma clone that constitutively expresses K+ currents carried by HERG channels (IHERG), as well as in human embryonic kidney 293 cells stably transfected with HERG cDNA, extracellular perfusion with 3 μm cetirizine did not exert any inhibitory action on IHERG. Astemizole (3 μm), on the other hand, was highly effective. Terfenadine (3 μm) caused a marked (≈80%) inhibition of IHERG in SH-SY5Y cells, whereas loratadine, at the same concentration, caused a 40% blockade. Furthermore, the application of cetirizine (3 μm) on the intracellular side of the membrane of HERG-transfected human embryonic kidney 293 cells did not affect IHERG, whereas the same intracellular concentration of astemizole caused a complete block. The results of the current study suggest that second-generation antihistamines display marked differences in their ability to block HERG K+ channels. Cetirizine in particular, which possesses more polar and smaller substituent groups attached to the tertiary amine compared with other antihistamines, lacks HERG-blocking properties, possibly explaining the absence of torsade de pointes ventricular arrhythmias associated with its therapeutical use.

Footnotes

  • Send reprint requests to: Dr. Maurizio Taglialatela, Department of Neurosciences, Section of Pharmacology, School of Medicine, University of Naples, Federico II, Via S. Pansini 5, 80131 Naples, Italy. E-mail: mtaglial{at}unina.it

  • The study was supported by Telethon Grants 748 and 1058 (M.T.); National Research Council (CNR) Grants 95.02452.CT04 (M.T.), 95.02857.CT04 (L.A.), and 95.00856.PF41 (G.M.); Ministero dell’Università e della Ricerca Scientifica e Tecnologica 60% and 40% (L.A. and G.M.); and a grant from the Regione Campania (L.A.).

  • Abbreviations:
    IHERG
    K+currents carried by HERG channels
    HEK
    human embryonic kidney
    Ikr
    Rapid component of the repolarizing K+current in cardiac cells, EGTA, ethylene glycol bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
    HEPES
    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
    • Received November 4, 1997.
    • Accepted March 20, 1998.
« Previous | Next Article »Table of Contents